Trial Profile
A Phase 2, Open-Label, Multicenter, Multi-Dose Study to Evaluate the Pharmacokinetics and Tolerability of Paricalcitol Injection in Chronic Kidney Disease Stage 5 Subjects With Secondary Hyperparathyroidism Undergoing Haemodialysis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jun 2014
Price :
$35
*
At a glance
- Drugs Paricalcitol (Primary)
- Indications Secondary hyperparathyroidism
- Focus Pharmacokinetics
- Sponsors Abbott Laboratories
- 17 Jun 2014 New trial record